Literature DB >> 23561470

Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications.

John C Riches1, John G Gribben.   

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Although significant advances have been made in the treatment of CLL in the last decade, it remains incurable. Treatments may be too toxic for some elderly patients, who constitute most of the individuals with this disease, and there remain subgroups of patients for which this therapy has minimal activity. This article summarizes the current understanding of the immune defects in CLL. It also examines the potential clinical implications of these findings.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23561470     DOI: 10.1016/j.hoc.2013.01.003

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  41 in total

1.  Ibrutinib treatment improves T cell number and function in CLL patients.

Authors:  Meixiao Long; Kyle Beckwith; Priscilla Do; Bethany L Mundy; Amber Gordon; Amy M Lehman; Kami J Maddocks; Carolyn Cheney; Jeffrey A Jones; Joseph M Flynn; Leslie A Andritsos; Farrukh Awan; Joseph A Fraietta; Carl H June; Marcela V Maus; Jennifer A Woyach; Michael A Caligiuri; Amy J Johnson; Natarajan Muthusamy; John C Byrd
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

Review 2.  Targeted therapy for chronic lymphocytic leukemia: current status and future directions.

Authors:  Jon E Arnason; Jennifer R Brown
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

3.  Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.

Authors:  Qingsong Yin; Mariela Sivina; Harlan Robins; Erik Yusko; Marissa Vignali; Susan O'Brien; Michael J Keating; Alessandra Ferrajoli; Zeev Estrov; Nitin Jain; William G Wierda; Jan A Burger
Journal:  J Immunol       Date:  2017-01-11       Impact factor: 5.422

4.  Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.

Authors:  Fabienne McClanahan; John C Riches; Shaun Miller; William P Day; Eleni Kotsiou; Donna Neuberg; Carlo M Croce; Melania Capasso; John G Gribben
Journal:  Blood       Date:  2015-05-15       Impact factor: 22.113

Review 5.  Antibody-modified T cells: CARs take the front seat for hematologic malignancies.

Authors:  Marcela V Maus; Stephan A Grupp; David L Porter; Carl H June
Journal:  Blood       Date:  2014-02-27       Impact factor: 22.113

6.  Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia.

Authors:  Iris de Weerdt; Vera van Hoeven; J Marius Munneke; Sanne Endstra; Tom Hofland; Mette D Hazenberg; Arnon P Kater
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

7.  Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia.

Authors:  Mónica Villa-Álvarez; Seila Lorenzo-Herrero; Ana P Gonzalez-Rodriguez; Alejandro López-Soto; Angel R Payer; Esther Gonzalez-Garcia; Leticia Huergo-Zapico; Segundo Gonzalez
Journal:  Oncoimmunology       Date:  2017-07-20       Impact factor: 8.110

Review 8.  Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.

Authors:  Yi Xia; L Jeffrey Medeiros; Ken H Young
Journal:  Biochim Biophys Acta       Date:  2015-10-16

Review 9.  Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach.

Authors:  Paolo Strati; Alessandra Ferrajoli
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

Review 10.  CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.

Authors:  Nathan Singh; Noelle V Frey; Stephan A Grupp; Shannon L Maude
Journal:  Curr Treat Options Oncol       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.